MER 4101

Drug Profile

MER 4101

Alternative Names: MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine; MER4101

Latest Information Update: 02 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mercia Pharma Inc
  • Developer Mercia Pharma Inc; Nova Immunotherapeutics Limited
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Influenza virus infections

Most Recent Events

  • 04 Oct 2017 Adverse events and immunogenicity data from a phase I trial in Influenza virus infections (In volunteers, In the elderly) presented at the IDWeek 2017 (IDW-2017)
  • 01 Jul 2015 Phase-I clinical trials in Influenza virus infections (In volunteers, In the elderly) in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top